BEDMINSTER, N.J., Oct. 14, 2019 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical stage biopharmaceutical company, today announced that it has initiated its Phase 2 ...

This double-blind trial enrolled adults with HIV-associated cryptococcal meningitis in Vietnam, Thailand, Indonesia, Laos, Uganda, and Malawi. All patients received combination antifungal therapy of ...

A common first-line treatment approach for cryptococcal meningitis in low-income countries is being compromised by the emergence of drug resistance, new University of Liverpool research warns.

A common first-line treatment approach for cryptococcal meningitis in low-income countries is being compromised by the emergence of drug resistance, new research warns. The findings highlight the need ...

The results of the ACTA trial were presented at the 9th IAS Conference on HIV Science held in Paris from 23 to 26 July 2017. Professor Thomas Harrison and his colleagues at St George's University of ...

"The results of this phase 3 [AMBITION-cm] trial make it clear that this approach is just as good as the current World Health Organization-recommended first-line treatment in preventing death," first ...

Gilles van Cutsem is affiliated with Doctors Without Borders, a member of the Cryptococcal Meningitis Advocacy Group, and Chair of the Patient Advisory Committee of the slow release flucytosine ...

(HealthDay News) — A case of cryptococcal meningitis with false-negative cerebrospinal fluid (CSF) culture results following receipt of capecitabine has been described in a case report published in ...

There is hope in the fight against cryptococcal meningitis, the second leading cause of death in patients with advanced HIV (previously called AIDS), as scientists work around the clock to release new ...

A 43-year-old woman with a past medical history significant for HIV complicated by cryptococcal meningitis and seizures presented to the ED after suffering a seizure and syncope.The following day she ...